LHRH-Targeted Drug Delivery Systems for Cancer Therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2017-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1389557516666161013111155PMID 27739358PMCID PMC6645782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multifunctional pH-sensitive micelles for tumor-specific uptake and cellular delivery

  2015cited by this paper
• Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy

  2015cited by this paper
• Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis.

  2015cited by this paper
• Ultrasmall [(64)Cu]Cu nanoclusters for targeting orthotopic lung tumors using accurate positron emission tomography imaging.

  2015cited by this paper
• ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression.

  2015cited by this paper
• Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy.

  2015cited by this paper
• Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer

  2014cited by this paper
• Dendrimer as nanocarrier for drug delivery

  2014cited by this paper
• LHRH-Conjugated Micelles for Targeted Delivery of Antiandrogen to Treat Advanced Prostate Cancer

  2014cited by this paper
• Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy

  2014cited by this paper
• GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.

  2014cited by this paper
• Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).

  2014cited by this paper
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

  2014cited by this paper
• LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer.

  2013cited by this paper
• Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells.

  2013cited by this paper
• Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug

  2013cited by this paper
• Nanotechnology and drug resistance.

  2013cited by this paper
• A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy.

  2013cited by this paper
• Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.

  2013cited by this paper
• Luteinizing-hormone-releasing-hormone-containing biodegradable polymer micelles for enhanced intracellular drug delivery.

  2013cited by this paper
• Nanotechnology approaches for personalized treatment of multidrug resistant cancers.

  2013cited by this paper
• Receptor-Targeting Phthalocyanine Photosensitizer for Improving Antitumor Photocytotoxicity

  2012cited by this paper
• GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.

  2012cited by this paper
• Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety.

  2012cited by this paper
• AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

  2012cited by this paper
• GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies.

  2012cited by this paper
• Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes.

  2011cited by this paper
• In vitro degradation and antitumor activity of oxime bond-linked daunorubicin–GnRH-III bioconjugates and DNA-binding properties of daunorubicin–amino acid metabolites

  2011cited by this paper
• Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA

  2011cited by this paper
• [DLys6]‐luteinizing hormone releasing hormone–curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo

  2011cited by this paper
• Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.

  2011cited by this paper
• Targeted drug delivery to tumors: myths, reality and possibility.

  2011cited by this paper
• A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging.

  2011influential reference
• Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

  2011influential reference
• Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide

  2011cited by this paper
• Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Clinical ression of Receptors for Luteinizing Hormone-Releasing mone ( LH-RH ) in Prostate Cancers following Therapy R LH-RH Agonists

  2010cited by this paper
• LHRH-targeted nanoparticles for cancer therapeutics.

  2010cited by this paper
• To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

  2010cited by this paper
• Passive and active drug targeting: drug delivery to tumors as an example.

  2010cited by this paper
• Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists

  2010cited by this paper
• Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.

  2010cited by this paper
• Receptor-mediated tumor targeting based on peptide hormones

  2010cited by this paper
• Novel insights into GnRH receptor activity: role in the control of human glioblastoma cell proliferation.

  2009cited by this paper
• FePt nanoparticles as an Fe reservoir for controlled Fe release and tumor inhibition.

  2009influential reference
• Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

  2009cited by this paper
• Direct anticancer activity of gonadotropin-releasing hormone-III.

  2009cited by this paper
• Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

  2009cited by this paper
• Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting.

  2009cited by this paper
• Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.

  2009cited by this paper
• Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?

  2008cited by this paper
• Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.

  2008cited by this paper
• LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI.

  2008cited by this paper
• New derivatives of GnRH as potential anticancer therapeutic agents.

  2008cited by this paper
• FePt@CoS(2) yolk-shell nanocrystals as a potent agent to kill HeLa cells.

  2007cited by this paper
• Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

  2007cited by this paper
• Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.

  2007cited by this paper
• Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy

  2006cited by this paper
• Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases.

  2006cited by this paper
• Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.

  2006cited by this paper
• Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

  2005cited by this paper
• Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1

  2005cited by this paper
• Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

  2005cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer.

  2004cited by this paper
• Chemotherapy targeted to cancers through tumoral hormone receptors.

  2004cited by this paper
• Evidence for LHRH-Receptor Expression in Human Airway Epithelial (Calu-3) Cells and Its Role in the Transport of an LHRH Agonist

  2004cited by this paper
• Targeting tumor cells.

  2003cited by this paper
• Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues.

  2003cited by this paper
• Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.

  2003cited by this paper
• Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.

  2003cited by this paper
• Targeted Proapoptotic LHRH-BH3 Peptide

  2003cited by this paper
• Peptide receptors as molecular targets for cancer diagnosis and therapy.

  2003cited by this paper
• New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.

  2003cited by this paper
• Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.

  2002cited by this paper
• Identification of tumour-associated t-cell epitopes for vaccine development

  2002cited by this paper
• Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.

  2002cited by this paper
• Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells.

  2002cited by this paper
• Lamprey Gonadotropin Hormone‐Releasing Hormone‐III has No Selective Follicle‐Stimulating Hormone‐Releasing Effect In Rats

  2002cited by this paper
• A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers.

  2002cited by this paper
• PEG drugs: an overview.

  2001influential reference
• Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.

  2001cited by this paper
• Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers.

  2001cited by this paper
• LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer.

  2000cited by this paper
• Evidence for co-ordinated changes between vascular endothelial growth factor and nitric oxide synthase III immunoreactivity, the functional status of the thyroid follicles, and the microvascular bed during chronic stimulation by low iodine and propylthiouracyl in old mice.

  2000cited by this paper
• Anti-Gonadotropin Releasing Hormone Vaccines and Their Potential Use in the Treatment of Hormone-Responsive Cancers

  1999cited by this paper
• Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.

  1999cited by this paper
• Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

  1996cited by this paper
• Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.

  1995cited by this paper
• Gonadotropin-releasing hormone and its analogs.

  1994cited by this paper
• Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain.

  1993cited by this paper
• Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.

  1991cited by this paper
• LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas.

  1991cited by this paper
• Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.

  1989cited by this paper
• Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.

  1989cited by this paper
• The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary.

  1987cited by this paper
• Hypothalamic regulatory hormones.

  1978cited by this paper
• Hypothalamic Regulatory Hormones

  1973cited by this paper
• Reproductive Biology and Endocrinology Role of Gonadotropin-releasing Hormone (gnrh) in Ovarian Cancer

  year unknowncited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Harnessing artificial intelligence for theragnostic applications: Current landscape and future directions

  2025cites this paper
• Luteinizing Hormone-Releasing Hormone (LHRH)-Targeted Treatment in Ovarian Cancer

  2025cites this paper
• The Involvement of the Peptidergic Systems in Breast Cancer Development

  2025cites this paper
• Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review

  2025cites this paper
• A stepwise responsive Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS drug delivery vector system for overcoming drug resistance in immunotherapy of hepatocellular carcinoma

  2025cites this paper
• Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer

  2025cites this paper
• DiWB‐1: A Luteinizing Hormone Releasing Hormone (LHRH)‐Targeted Peptide‐Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy

  2025cites this paper
• In vitro assessment of polyethylene glycol-coated iron oxide nanoparticles integrating luteinizing hormone releasing-hormone targeted magnetic hyperthermia and doxorubicin for lung and breast cancer cells.

  2025cites this paper
• Multifunctional Tandem Peptide Mediates Targeted siRNA Delivery to Ovarian Cancer Cells.

  2025cites this paper
• Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor therapy.

  2025cites this paper
• Nanoformulations: Reforming treatment for non-small cell lung cancer metastasis.

  2025cites this paper
• Peptides on patrol: Carrier systems for targeted delivery.

  2025cites this paper
• Precision‐Engineered Cobalt‐Doped Iron Oxide Nanoparticles: From Octahedron Seeds to Cubical Bipyramids for Enhanced Magnetic Hyperthermia

  2025cites this paper
• Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.

  2024cites this paper
• Multifunctional approach with LHRH-mediated PLGA nanoconjugate for site-specific codelivery of curcumin and BCL2 siRNA in mice lung cancer

  2024cites this paper
• Revolutionizing Lung Cancer Treatment: Nanotechnology-Driven Advances in Targeted Drug Delivery and Novel Therapeutic Strategies

  2024cites this paper
• Targeted Lipid-Based Drug Delivery Systems for Lung Cancer Therapy

  2024cites this paper
• Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy.

  2024cites this paper
• Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization

  2024cites this paper
• Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

  2024cites this paper
• In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

  2024cites this paper
• Nanoparticle-Based Combination Therapy for Ovarian Cancer.

  2023cites this paper
• Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer

  2023cites this paper
• Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues.

  2023cites this paper
• Evolving strategies and application of proteins and peptide therapeutics in cancer treatment.

  2023cites this paper
• The use of nanoparticles for targeted drug delivery in non-small cell lung cancer

  2023cites this paper
• Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways

  2022cites this paper
• Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

  2022cites this paper
• An Advanced Thermal Decomposition Method to Produce Magnetic Nanoparticles with Ultrahigh Heating Efficiency for Systemic Magnetic Hyperthermia

  2022cites this paper
• Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine

  2022cites this paper
• Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

  2022cites this paper
• Advances in Lung Cancer Treatment Using Nanomedicines

  2022cites this paper
• Epigenetic repression of gonadotropin gene expression via a GnRH-mediated DNA delivery system

  2022cites this paper
• Advancement in magnetic hyperthermia-based targeted therapy for cancer treatment.

  2022cites this paper
• Recent Advances and Trends in Chemical CPP–Drug Conjugation Techniques

  2021cites this paper
• Lipoamino Acid-Modi ed GnRH Analogs with Receptor-Mediated Antiproliferative Activity in Prostate and Ovarian Cancer Cells

  2021cites this paper
• Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

  2021cites this paper
• Lipoamino acid-modified GnRH analogs with receptor-mediated antiproliferative activity in prostate and ovarian cancer cells

  2021cites this paper
• Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

  2021cites this paper
• Recent advances in active targeting of nanomaterials for anticancer drug delivery.

  2021cites this paper
• Decapeptide Modified Doxorubicin Loaded Solid Lipid Nanoparticles as Targeted Drug Delivery System against Prostate Cancer.

  2021cites this paper
• Peptide-drug conjugates in targeted drug delivery to cancer

  2021cites this paper
• Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

  2021cites this paper
• Peptides-based therapy and diagnosis. Strategies for non-invasive therapies in cancer

  2021cites this paper
• The role of peptide-based therapeutics in oncotherapy

  2021cites this paper
• Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges

  2021cites this paper
• Emerging Lipid-Based Nanomaterials for Cancer Theranostics

  2021cites this paper
• Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer

  2020cites this paper
• LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

  2020cites this paper
• Ultrabright NIR‐II Emissive Polymer Dots for Metastatic Ovarian Cancer Detection

  2020cites this paper
• Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.

  2020cites this paper
• Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment.

  2020cites this paper
• LHRH‐Targeted Redox‐Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple‐Negative Breast Cancer

  2020cites this paper
• Systemically Delivered Magnetic Hyperthermia for Prostate Cancer Treatment

  2020cites this paper
• LHRH/TAT dual peptides-conjugated polymeric vesicles for PTT enhanced chemotherapy to overcome hepatocellular carcinoma

  2020cites this paper
• Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging

  2020cites this paper
• Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery

  2020cites this paper
• Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?

  2019cites this paper
• A review on Targeting Nanoparticles for Breast Cancer.

  2019cites this paper
• Rational Design of Hybrid Peptides: A Novel Drug Design Approach

  2019cites this paper
• Aptamer-templated silver nanoclusters embedded in zirconium metal–organic framework for targeted antitumor drug delivery

  2019cites this paper
• Subclinical Lipopolysaccharide from Salmonella Enteritidis Induces Dysregulation of Bioactive Substances from Selected Brain Sections and Glands of Neuroendocrine Axes

  2019cites this paper
• The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer

  2019cites this paper
• Nanocarrier-based systems for targeted and site specific therapeutic delivery.

  2019cites this paper
• Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer

  2018cites this paper
• Target-specific delivery of siRNA into hepatoma cells’ cytoplasm by bifunctional carrier peptide

  2016cites this paper
• Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.

  2016cites this paper
• Lipoamino Acid-Modied GnRH Analogs with Receptor-Mediated Antiproliferative Activity in Prostate and Ovarian Cancer Cells

  year unknowncites this paper